Pancreatitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, March 2012, Pages: 57

Pancreatitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Pancreatitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Pancreatitis Therapeutics market. The report identifies the key trends shaping and driving the global Pancreatitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Pancreatitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Pancreatitis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Pancreatitis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Pancreatitis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Pancreatitis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Pancreatitis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Pancreatitis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Pancreatitis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Pancreatitis Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Pancreatitis Therapeutics Introduction
2.1 Overview
2.2 Classification of Pancreatitis
2.3 Epidemiology
2.4 Etiology
2.5 Pathophysiology
2.6 Signs and Symptoms
2.7 Complications
2.8 Diagnosis
2.8.1 Physical Examination
2.8.2 Stool Tests
2.8.3 Blood Tests
2.8.4 Imaging Tests
2.9 Treatment
2.9.1 Alcohol Avoidance
2.9.2 Hospitalization
2.9.3 Surgery
2.10 GlobalData Pipeline Report Guidance
3 Pancreatitis Therapeutics - Market Characterization
3.1 Pancreatitis Therapeutics Market Size (2006-2011) - Global
3.2 Pancreatitis Therapeutics Market Forecast (2011-2019) - Global
3.3 Pancreatitis Therapeutics Market Size (2006-2011) - US
3.4 Pancreatitis Therapeutics Market Forecast (2011-2019) - The US
3.5 Pancreatitis Therapeutics Market Size (2006-2011) - The UK
3.6 Pancreatitis Therapeutics Market Forecast (2011-2019) - The UK
3.7 Pancreatitis Therapeutics Market Size (2006-2011) - France
3.8 Pancreatitis Therapeutics Market Forecast (2011-2019)- France
3.9 Pancreatitis Therapeutics Market Size (2006-2011) - Germany
3.10 Pancreatitis Therapeutics Market Forecast (2011-2019) - Germany
3.11 Pancreatitis Therapeutics Market Size (2006-2011) - Italy
3.12 Pancreatitis Therapeutics Market Forecast (2011-2019) - Italy
3.13 Pancreatitis Therapeutics Market Size (2006-2011) - Spain
3.14 Pancreatitis Therapeutics Market Forecast (2011-2019) - Spain
3.15 Pancreatitis Therapeutics Market Size (2006-2011) - Japan
3.16 Pancreatitis Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Pancreatitis Therapeutics Market
3.17.1 Drivers for the Pancreatitis Therapeutics Market
3.17.2 Barriers to the Pancreatitis Therapeutics Market
3.18 .Key Events Impacting the Future Market
3.18.1 Opportunity and Unmet Need
3.19 Key Takeaway
4 Pancreatitis Therapeutics Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Profiles of the Commonly Used Products in the Pancreatitis Therapeutics Market
4.2.1 Pancrelipase (Zenpep, Creon, Pancreaze)
4.2.2 Non-steroidal Anti-inflammatory Drugs
4.2.3 Opioids
4.2.4 Antibiotics
4.2.5 Tricyclic Antidepressants
4.3 Key Takeaway
5 Pancreatitis Therapeutics Market - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Pancreatitis Pipeline Analysis - Pipeline by Clinical Phases of Development
5.3.1 Pancreatitis Therapeutics – Phase III Pipeline
5.3.2 Pancreatitis Therapeutics – Phase II/III Pipeline
5.3.3 Pancreatitis Therapeutics – Phase II Pipeline
5.3.4 Pancreatitis Therapeutics – Phase I/II Pipeline
5.3.5 Pancreatitis Therapeutics – Phase I Pipeline
5.3.6 Pancreatitis Therapeutics – Preclinical Pipeline
5.4 Pancreatitis Pipeline by Mechanism of Action
5.5 Pancreatitis Technology Trends Analytical Framework
5.6 Molecule Profile for Key Drugs under Clinical Development
5.6.1 Namisol
5.7 Key Takeaway
6 Pancreatitis Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (The US, EU5 and Japan)
6.2 Clinical Trials Mapping by Phase
6.3 Clinical Trials Mapping by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Pancreatitis Therapeutics Clinical Trials
7 Pancreatitis Therapeutics: Strategic Assessment
7.1 Future Market Competition Scenario
8 Pancreatitis Therapeutics: Future Players in the Market
8.1 Introduction
8.2 Company Profiles
8.2.1 Echo Pharmaceuticals
9 Pancreatitis Therapeutics: Licensing and Partnership Deals
10 Pancreatitis Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Historical Prevalence of Pancreatitis for Seven Major Markets
Table 2: Forecasted Prevalence of Pancreatitis for Seven Major Markets
Table 3: Pancreatitis Therapeutics Market, Global, Revenue ($m), 2006–2011
Table 4: Pancreatitis Therapeutics Market, Global, Forecast ($m), 2011–2019
Table 5: Pancreatitis Therapeutics Market, The US, Revenue ($m), 2006–2011
Table 6: Pancreatitis Therapeutics Market, The US, Revenue ($m), 2011–2019
Table 7: Pancreatitis Therapeutics Market, The UK, Revenue ($m), 2006–2011
Table 8: Pancreatitis Therapeutics Market, The UK, Forecast ($m), 2011–2019
Table 9: Pancreatitis Therapeutics Market, France, Revenue ($m), 2006–2011
Table 10: Pancreatitis Therapeutics Market, France, Forecast ($m), 2011–2019
Table 11: Pancreatitis Therapeutics Market, Germany, Revenue ($m), 2006–2011
Table 12: Pancreatitis Therapeutics Market, Germany, Forecast ($m), 2011–2019
Table 13: Pancreatitis Therapeutics Market, Italy, Revenue ($m), 2006–2011
Table 14: Pancreatitis Therapeutics Market, Italy, Forecast ($m), 2011–2019
Table 15: Pancreatitis Therapeutics Market, Spain, Revenue ($m), 2006–2011
Table 16: Pancreatitis Therapeutics Market, Spain, Forecast ($m), 2011–2019
Table 17: Pancreatitis Therapeutics Market, Japan, Revenue ($m), 2006–2011
Table 18: Pancreatitis Therapeutics Market, Japan, Forecast ($m), 2011–2019
Table 19: Pancreatitis Therapeutics – Phase III Pipeline
Table 20: Pancreatitis Therapeutics – Phase II/III Pipeline
Table 21: Pancreatitis Therapeutics – Phase II Pipeline
Table 22: Pancreatitis Therapeutics – Phase I/II Pipeline
Table 23: Pancreatitis Therapeutics – Phase I Pipeline
Table 24: Pancreatitis Therapeutics – Preclinical Pipeline
Table 25: Pancreatitis Therapeutics – Discovery Pipeline
Table 26: Pancreatitis Therapeutics – Clinical Trials by Country, 2012
Table 27: Pancreatitis Therapeutics – Clinical Trials by Phase, 2012
Table 28: Pancreatitis Therapeutics – Clinical Trials by Status, 2012
Table 29: Pancreatitis Therapeutics – Clinical Trials by Overall Sponsors, 2012
Table 30: Pancreatitis Therapeutics – Clinical Trials by Prominent Sponsors, 2012
Table 31: Pancreatitis Therapeutics Clinical Trial – Company Sponsors by Phase, 2012
Table 32: Echo Pharmaceuticals – Pancreatitis Pipeline
Table 33: Licensing and Partnership Deals

1.2 List of Figures
Figure 1: Classification of Pancreatitis
Figure 2: Patient Share of Pancreatitis in the Seven Major Markets, 2011
Figure 3: Tests Used for the Diagnosis of Pancreatitis
Figure 4: Computerized Tomography Scan
Figure 5: Pancreatitis Therapeutics Market, Global, Revenue ($m), 2006–2011
Figure 6: Pancreatitis Therapeutics, Market Share ($m), 2011
Figure 7: Pancreatitis Therapeutics Market, Global, Forecast ($m), 2011–2019
Figure 8: Pancreatitis Therapeutics, Market Share ($m), 2019
Figure 9: Pancreatitis Therapeutics Market, The US, Revenue ($m), 2006–2011
Figure 10: Pancreatitis Therapeutics Market, The US, Forecast ($m), 2011–2019
Figure 11: Pancreatitis Therapeutics Market, The UK, Revenue ($m), 2006–2011
Figure 12: Pancreatitis Therapeutics Market, The UK, Forecast ($m), 2011–2019
Figure 13: Pancreatitis Therapeutics Market, France, Revenue ($m), 2006–2011
Figure 14: Pancreatitis Therapeutics Market, France, Forecast ($m), 2011–2019
Figure 15: Pancreatitis Therapeutics Market, Germany, Revenue ($m), 2006–2011
Figure 16: Pancreatitis Therapeutics Market, Germany, Forecast ($m), 2011–2019
Figure 17: Pancreatitis Therapeutics Market, Italy, Revenue ($m), 2006–2011
Figure 18: Pancreatitis Therapeutics Market, Italy, Forecast ($m), 2011–2019
Figure 19: Pancreatitis Therapeutics Market, Spain, Revenue ($m), 2006–2011
Figure 20: Pancreatitis Therapeutics Market, Spain, Forecast ($m), 2011–2019
Figure 21: Pancreatitis Therapeutics Market, Japan, Revenue ($m), 2006–2011
Figure 22: Pancreatitis Therapeutics Market, Japan, Forecast ($m), 2011–2019
Figure 23: Pancreatitis Therapeutics, Key Events Impacting the Future Market, 2012
Figure 24: Opportunity and Unmet Need in the Pancreatitis Therapeutics Market, 2012
Figure 25: Pancreatitis Therapeutics Market - Strategic Competitor Assessment, 2012
Figure 26: Pancreatitis Therapeutics - Pipeline by Phase of Clinical Development, 2012
Figure 27: Pancreatitis Therapeutics – Clinical Pipeline by Mechanism of Action, 2012
Figure 28: Pancreatitis Therapeutics - Technology Trends Analytical Framework, 2012
Figure 29: Pancreatitis Therapeutics – Clinical Trials by Country, 2012
Figure 30: Pancreatitis Therapeutics – Clinical Trials by Phase, 2012
Figure 31: Pancreatitis Therapeutics – Clinical Trials by Status, 2012
Figure 32: Pancreatitis Therapeutics – Clinical Trials by Overall Sponsors, 2012
Figure 33: Pancreatitis Therapeutics – Clinical Trials by Prominent Sponsors, 2012
Figure 34: Pancreatitis Therapeutics Clinical Trial – Company Sponsors by Phase, 2012
Figure 35: Pancreatitis Therapeutics, Strategic Assessment, 2012
Figure 36: Pancreatitis Therapeutics Market – Clinical Pipeline by Company, 2012
Figure 37: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Pancreatitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global pancreatitis market. It identifies the key trends shaping and driving the global market and provides insights into the prevalent competitive landscape and the emerging players expected to alter the positioning of the current leaders. Most importantly, the report provides valuable insights into the pipeline products within the global pancreatitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Pancreatitis Therapeutics Market is Forecast to Decline until 2019

GlobalData estimates that the global pancreatitis therapeutics market was worth $36m in 2011 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 3.6% to $47.7m by 2019. The current treatment options for pancreatitis offer only symptomatic relief and are primarily generic. There are no currently approved disease-modifying drugs in the market and only one in the pipeline (somatostatin). As a result, the market is expected to show slow growth until 2019.

The Pancreatitis Therapeutics Market has Significant Unmet Need

GlobalData has found that the pancreatitis therapeutics market has significant unmet need, implying that the market is moderately served by the current products in terms of efficacy and that there is a good potential for new entrants. Pancreatitis therapies are largely targeted at reducing inflammation, pain and depression, but the current treatment options are limited. They include symptomatic treatment with simple opioid analgesics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), antidepressants and pancreatic enzyme supplements. Non selective NSAIDs and opioids are effective in the early to mid stages of pancreatitis, but often fail to provide adequate chronic pain relief. NSAIDs also cause gastrointestinal complications in a high number of patients.

The current market lacks disease-modifying drugs, resulting in significant unmet need in the treatment of pancreatitis. The only disease-modifying drug in the late stage of the pipeline is somatostatin, which is currently undergoing a university-sponsored trial. This unmet need is expected to persist during the forecast period as patients are forced to depend on symptomatic relief.

Scope for Entrants with Better Efficacy and Safety Profiles

The pancreatitis therapeutics market is underserved by the currently marketed drugs. Pancrelipase is the only approved drug for chronic pancreatitis, and although it has shown high levels of safety, the same cannot be said for efficacy. As a result, there is huge potential for new entrants with drugs that can halt or reverse disease progression as well as offering good efficacy and safety profiles in both acute and chronic pancreatitis. There is also huge potential for novel therapies with better symptomatic relief.

Echo Pharmaceuticals

Customers who bought this item also bought

• Medical Nutrition - A Global Market Overview
• Global Osteoporosis Therapeutics Market: Market Forecast, Patient Flow,Competitive Landscape, and Pipeline Analysis
• Disinfectants - Global Strategic Business Report
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Diabetes Diagnostics - Global Strategic Business Report
• Molecular Diagnostics - Global Strategic Business Report
• Cord Blood Stem Cells – A Global Market Overview
• Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
• The Incidence and Prevalence Database: Global Incidence, Prevalence, Morbidity, Comorbidity, Cost Data, Symptoms and Many Other Health Issues for over 4,500 Diseases and Procedures
• Medical Oxygen Systems - Global Strategic Business Report